Charles Brenton Huggins
Charles Brenton Huggins (September 22, 1901 – January 12, 1997) was a Canadian-American physiologist and cancer researcher who made groundbreaking discoveries in the field of cancer treatment. His pioneering work on the hormonal treatment of prostate cancer earned him the Nobel Prize in Physiology or Medicine in 1966, which he shared with Peyton Rous for their discoveries concerning hormonal treatment of prostatic cancer. Huggins's research fundamentally changed the way cancer is treated, introducing the concept of hormone therapy as an effective approach for managing certain types of cancers.
Early Life and Education[edit | edit source]
Charles Brenton Huggins was born in Halifax, Nova Scotia, Canada. He pursued his undergraduate education at Acadia University, where he received a Bachelor of Science degree. Following this, Huggins attended Harvard University, where he earned his M.D. degree. His early interest in medical research led him to focus on cancer treatment, a field that was in its nascent stages during the early 20th century.
Career and Research[edit | edit source]
After completing his education, Huggins began his career at the University of Chicago, where he would spend the majority of his professional life. It was here that he conducted his most notable research on prostate cancer. Huggins discovered that prostate cancer's growth could be inhibited by castrating the patient or by administering estrogen. This was the first demonstration that cancer could be controlled by manipulating hormone levels, a discovery that opened new avenues for cancer treatment.
Huggins's work extended beyond prostate cancer. He also conducted significant research on breast cancer, showing that the removal of the ovaries could slow the progression of the disease in some patients. This further solidified the role of hormones in cancer growth and treatment.
Nobel Prize and Later Years[edit | edit source]
In 1966, Charles Brenton Huggins was awarded the Nobel Prize in Physiology or Medicine for his discoveries concerning hormonal treatment of prostatic cancer. This accolade was a testament to the impact of his work on the medical field, particularly in the area of cancer treatment.
Following his Nobel Prize win, Huggins continued to work and teach at the University of Chicago. He remained active in the research community, contributing to the field until his retirement. Huggins passed away on January 12, 1997, leaving behind a legacy that continues to influence the treatment of cancer.
Legacy[edit | edit source]
Charles Brenton Huggins's research fundamentally changed the understanding and treatment of cancer. His work on hormone therapy has saved countless lives and continues to be a cornerstone of cancer treatment. Huggins is remembered not only for his scientific achievements but also for his dedication to improving patient care through research.
See Also[edit | edit source]
References[edit | edit source]
Search WikiMD
Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro / Zepbound) available.
Advertise on WikiMD
WikiMD's Wellness Encyclopedia |
Let Food Be Thy Medicine Medicine Thy Food - Hippocrates |
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
WikiMD is not a substitute for professional medical advice. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates Wikipedia, licensed under CC BY SA or similar.
Contributors: Prab R. Tumpati, MD